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1. Introduction 
The history of genetic variations in drug responses can be traced to the 1950s with the 
observations that muscle relaxant suxamethonium chloride and drugs metabolized by N-
acetyl transferase exhibit differences in response in patients. One in 3500 caucasians was 
found to possess the less efficient variant of the enzyme, butyryl chlolinesterase that 
metabolizes suxamethonium chloride; an anaesthetic agent.As a consequence, the drug’s 
effect is prolonged with slower recovery from surgical paralysis. 
The term pharmacogenetics evolved from the combination of two areas of study namely 
pharmacology and genetics. Pharmacology is the study of how drugs work in the body and 
genetics is the study of how characteristics that result from the action of genes  acting together 
are inherited and how they function in the cells of the body . Therefore, pharmacogenetics 
refers to genetic differences in metabolic pathways which can affect individual responses to 
drugs both in terms of therapy and adverse effects. Pharmacogenetics helps our 
understanding of why some individuals respond to drugs and others do not and why some 
require higher or lower doses to achieve  optimal therapeutic responses. 
In addition, pharmacogenetic information helps the physician to identify those patients who 
will respond favourably to therapy or develop side effects.  
A recent offshoot of pharmacogenetics, termed pharmacogenomics is the study of drug 
response in the context of the entire genome. Pharmacogenomics facilitates information on 
variations in all the genes in a group of individuals simultaneously to determine the basis of 
variants in drug response. It is therefore not uncommon to find the two being used 
interchangeably.However for the purpose of this chapter, pharmacogenetics will be the focus. 
Individual variation in response to  drug ranges from failure to respond to drug therapy to 
drug to drug interactions when several drugs are taken simultaneously. The clinical 
consequences range from patients’ discomfort through serious clinical illness to the 
occasional fatality. Approximately 7% of patients are affected by adverse drug reactions, 
increasing the overall hospital costs by 19% and drug costs by 15%. Some 0.3%  of adverse 
drug reactions have fatal outcome (Topic 2010). 
1.1 Individual variation in drug effects 
Variation in drug metabolism and drug response among individuals of the same body 
weight and on the same drug dose can be due to temporary causes such as transient enzyme 
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inhibition, induction or permanent causes such as genetic  mutation, gene deletion or 
amplification. (Shenfield 2004). 
Genetic variability is known to affect drug absorption, drug metabolism and drug 
interactions with receptors. These therefore form the basis for slow or rapid drug 
absorption, poor, efficient or ultrarapid drug metabolism and poor or efficient receptor 
interactions. 
A genetic mutation frequency exceeding 10% of a population is considered a genetic 
polymorphism (Meyer 2000). Genetic polymorphism based on drug metabolizing ability is 
related to four phenotypic classes. The phenotype of extensive or normal drug metabolizers 
(EM) is characteristic of the normal population .Individuals are either homozygous or 
heterozygous for wild type allele. Those individuals who are heterozygous for the wild type 
allele may have intermediate metabolizer phenotype (IM) and may require lower than 
average drug dose for optimal therapeutic response. Those individuals with mutation or 
deletion of both alleles for the determinant of phenotypic response can  be classified as poor 
metabolizers (PM) and therefore prone to accumulation of drug substrates in their systems 
with attendant effects. The fourth class, termed the ultrarapid metabolizers (UM) possess  
enhanced drug metabolism capabilities due to gene amplification and are prone to drug 
failure because drug concentrations at normal doses are expected to be too low for 
therapeutic effects (Meyer 2000, Davies 2006). 
There are ethnical and racial differences in the frequency of variant alleles  and up to 10 – 
20% of patients belong to the risk groups. ( Evans 1986, Banjoko & Akinlade  2010). 
1.2 Mechanism of genetic polymorphism  
Pharmacogenetic polymorphism can manifest at the pharmacokinetic and 
pharmacodynamics levels. The pharmacokinetic level deals with gene polymorphism that 
modify concentrations of drugs and its metabolites at the site of their molecular action 
(polymorphism of drug metabolizing enzymes, drug transporters) whereas the 
pharmacodynamics level deal with polymorphism of action not related to its concentration 
(receptors, ion channels). Genetic variations  are the result of multiple mechanism such as 
insertion, deletion, variable tandem repeats and microsatellites but the most frequent 
polymorphism are point mutation or single nucleotide polymorphism (SNPS). Some of the 
polymorphism are without consequences but others cause synthesis of altered proteins, 
truncated proteins, unstable proteins or proteins at the level of expression. 
Genotype is the detailed gene structure of an individual whereas the more commonly 
measured phenotype is the outcome of metabolism of a drug in an individual. Since 
genotype is the result of interactions between genetic make up and the environment, it is not 
always concordant with phenotype. 
1.3 Consequences of pharmacogenetics 
The underpinning factors for the growing importance of pharmacogenetics are the necessity 
to prevent adverse drug reaction, obtain maximum benefits from drug therapy and reduce 
therapeutic failure. 
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Adverse drug reactions are thought to kill many hospitalized patients worldwide. In the US 
alone, the estimate of deaths attributable to drug reactions is about 100,000 annually and it is 
believed that many of these reactions are due to genetic variations. Thus many deaths are 
avoidable if genetic testing or genomic information of patients are available and utilized 
prior to therapy. 
Pharmacogenetics will therefore permit gene profiling to answer questions about drug 
responses and promote the design of better and safer drugs. In addition, individualized dosing 
has the potential of better therapeutic outcome. Therefore pharmacogenetics is expected to 
revolutionise drug dosing and therapy .However, there are still many challenges to  overcome. 
These include cost implications, standardization , quality control of testing, and relevance of 
biomarkers and  tests. Nevertheless, the advent of pharmacogenetics and establishment of 
guidelines by regulatory bodies like Food and Drugs Administration (FDA) European 
Medicines Agency (EMEA) and American Association of Clinical Chemists (AACC) are 
expected to impact individualized dosing of many drugs. 
1.4 Confounding issues in pharmacogenetics  
The understanding that drug response may be multifactoral helps us to recognize the 
importance of examining more than the classical “single gene-single protein concept which 
gave birth to pharmacogenomics. In addition, there are more evidences that modifications 
besides outright mutation of genes, for example, methylation of promoter region by epigenetic 
factor impact gene expression and drug responses. Moreover, genotype is not the only 
determinant of phenotype. For example, individuals whose genotypes falls extensive 
metabolizers via CYP2D6 can display a phenotype that would characterize them as poor 
metabolizers if they are co-administered low doses of quinidine which is a potent inhibitor of 
CYP2D6 . Therefore, differences   in phenotype does not necessarily translate into difference in 
pharmacologic response between subjects. In the same fashion, mutation of the genes may not 
necessarily translate into effect on drug metabolism (Henningson et al 2005). 
Because of significant racial differences in genetic composition, it is important that caution is 
exercised in the interpretation of genetic testing. For example different genotypes may give 
rise to the same phenotype.In addition, there are  varieties  of mutations in NAT2 that give 
rise to slow acetylator status. 
Furthermore the historical use of wild-type alleles and mutant alleles may not necessarily 
hold true for all the races hence the migration to the term reference and mutant alleles. 
2. Basic genetics  
Genetics is the study concerned with hereditary and variation. One of the most fundamental 
properties of all living organisms is the ability to reproduce. All organisms therefore inherit 
the genetic information specifying their structure and function from their parents. In the 
same manner, all cells arise from pre – existing cells, so the genetic material must be 
replicated and passed from a parent to progeny cell at each cell division. The hereditary 
molecules that are transmitted from one generation to the next i.e. inherited are called genes. 
These molecules (genes) reside in the deoxyribonucleic acid (DNA)  that exist within all 
cells. The DNA in conjunction with a protein matrix forms nucleoprotein and become 
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organized into structures called chromosomes located in the nucleus or nuclear region of 
cells. The genes contains coded information for the synthesis of proteins and some 
ribonucleic acids (RNA). Occasionally, a change may occur spontaneously in some part of 
the DNA. This change is called mutation and may result in an alteration of the code 
designated for a particular function resulting in production of a defective protein. 
A mutation may lead to a change in the physical appearance of an individual or change in 
some other measurable attributes of the organism called a character or trait. Through the 
process of mutation, a gene may be changed into two or more alternative forms called 
alleles. Each gene occupies a specific position on the chromosomes called the gene locus. All 
allelic forms of a gene therefore are found at corresponding positions on genetically similar 
(homologous) chromosomes.  
All the genes on a chromosomes are said to be linked to one another and to belong to the 
same linkage group. Since a gene can be changed to alternative forms by the process of 
mutation, a large number of alleles are theoretically possible in a population of individuals. 
Whenever more than two alleles are identified at a gene locus in a population, such  is 
described as multiple allele series.  
Genetic information is stored and transmitted in the four letter alphabet and language of 
DNA (A,C,G,T)  and ultimately expressed in the twenty letter alphabet of proteins. Protein 
biosynthesis is called translation because it involves the biochemical translation of 
information between languages. 
A capital letter is commonly used to designate the allele that is dominant to other alleles in 
the series. For example letter “R” for a character is dominant over ‘r’ which is an allele that 
is recessive to all others in the series .Intermediate in their degree of dominance between the 
two extremes are usually assigned the lower case letter with superscript which in this 
example is r*. Many genes may contribute to a single character or trait (polygenic traits) or 
traits exhibiting continuous variation. In addition, each gene may have multiple phenotypic 
effects (pleiotropy). 
Each character is controlled by a pair of genes. The progeny or offspring are therefore 
hybrids of the parents, inheriting a pair of gene, one each from each parent. For example for 
trait for tallness being represented by letter T, possible genetic composition are TT, Tt, and tt 
whereby T allele is dominant over t. It is expected that an offspring with tt genetic 
composition will be short while those with TT or Tt will be tall.  
The genetic composition of a trait is referred to as the genotype and the physical appearance 
corresponding to the genotype, in this example tallness is called the phenotype.With 
different generations of offsprings i.e. the filial generations, different genotypes and 
corresponding phenotypes are obtainable. 
The originator of the classical principles of genetics is Macgregor Mendel who made public the 
result of his study of peas breeding in 1865. Mendel studied the inheritance of a number of 
well defined traits in the pea such as seed colour and was able to deduce general rules for their 
transmission. He was the first to observe that each trait was determined by a pair of inherited 
factors later termed the genes. Mendel’s findings provided the template for determination of 
genotypes and phenotypes of different genetic diseases of humans, animals and plants and 
notable examples include: sickle cell disease, albinism and thalassaemias.  
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By 1900, Mendel’s laws of inheritance were well established and are thus stated: 
Law of segregation: Each parent possesses 2 copies of a unit of inheritance (now called the 
gene) for each trait. However, only one of these two genes (an allele) is transmitted through 
a gamete to the offspring. 
Law of independent assortment: says segregation  of one gene pair occurs independently of 
any other gene pair. 
2.1 Chromosomes, genes and inheritance 
Chromosomes are known to be carrier of genes. Most cells of higher plants and animals are 
diploid. i.e. they contain two copies of each chromosome. Formation of the germ cells; the 
sperm and egg involves a unique type of cell division termed meiosis. In this process, only 
one member of each chromosome pair is transmitted to each progeny cell. Therefore, the 
sperm and egg are haploid containing only one copy of each chromosome. The fusion of 
these two haploid cells at fertilization result in a new diploid organism; the offspring which 
consists of one member of each chromosome pair. Behaviour of chromosome pairs is 
directly related to their genes indicating a strong relationship between genes and 
chromosomes. 
Genetic alterations i.e. mutation which is the basis of genetic diseases was first identified in 
the experiment with Drosophilia melanogaster (the fruit fly) in the early 1900. Mutations in  
drosophila was observed to involve such phenotypes like eye colour and wing  shape. 
Experimented evidences revealed that the genes governing these traits are inherited 
independently of each other, suggesting that these genes are located on different 
chromosomes that segregate independently during meiosis. Other genes are inheritable as 
paired characteristics and such  are said to be linked to each other by virtue of being located 
on the same chromosome. The frequency of recombination between two linked genes 
depends on distance between them on the chromosomes. In addition, genes that are close to 
each other recombine less frequently than do genes further apart. Thus the differences with 
which the different genes recombine can be used to determine their relative position on the 
chromosome allowing the construction of a genetic map. 
2.2 Genes, proteins and enzymes 
Genes act by determining the structure of proteins which are responsible for directing cell 
metabolism through the activities of enzymes. Many genes encode enzymes that are 
important for catalysing biological synthesis (anabolic) and degradation (catabolic reactions) 
within a cell. These reactions grouped together into a series of reactions are called 
biochemical pathways and commence with the enzymes acting on their corresponding 
substrate. 
The first indication  linking genes and enzymes can be traced to 1909 when it was observed 
that patients suffering from phenylketonuria were suspected to have a genetic defect in the 
metabolism of the amino acid for phenylalanine.This line of thought was supported by the 
experiment of George Beadle and Edward Tatum in 1941 with the fungus; Neurospora cassa. 
Using mutant strains of the organism, they observed that each mutant required specific 
nutritional supplement such as a particular aminoacid for growth.Furthermore, the 
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requirement for a specific nutritional supplement correlates with the failure of the mutant to 
synthesize that particular compound. Thus each mutant resulted in a deficiency in a specific 
metabolic pathway. Since metabolic pathways are known to be controlled by enzymes, these 
findings gave rise to the one – gene – one enzyme hypothesis which by implication means 
that each gene specified the structure of a single enzyme. However, the revelation that genes 
not only codes for proteins and enzymes but tRNAs resulted in this hypothesis  being 
modified to one – gene – one – polypeptide concept. 
Transfer RNA’s (tRNAs) serve as adaptations between aminoacids and messenger RNA 
(mRNA) during translation. Prior to its use in protein synthesis, each aminoacid is attached 
by a specific enzyme to its appropriate tRNA. Base pairing between a recognition sequence 
in each tRNA and a complimentary sequence on the mRNA then directs the attached 
aminoacid to its correct position on the mRNA template. 
2.3 Genetic polymorphism  
Genetic polymorphism can be defined as differences in DNA sequence among individuals, 
groups or population. Genetic mutation can create genetic variance in a population and this 
can manifest in different ways. Somatic cell mutation can create a genetic variation in a cell 
population which may induce cancer and tumour when  such mutation takes place in 
repressor genes  controlling cell cycles such as p53 gene. On the other hand,germ line cell 
mutation can cause genetic diseases such as sickle cell disease, thalassemia, Parkinson’s 
disease as well as defect of biochemical pathway that influence drug – receptor interaction 
with attendant deleterious effects on patients. Point mutation such as a single base 
nucleotide substitution (SNP) are common particularly with adverse drug reactions. 
Mutation that occurs in germ line cell would be inherited by the progeny and these mutated 
genes can spread in a population through the fertilization process. Mutations that occur in 
coding frame of DNA region that are responsible for synthesis of specific products could 
give rise to genetic disease. Similarly, mutation that affects enzymes responsible for 
biotransformation of drugs particularly C450 gene family and pharmacokinetic and 
pharmacodynamic gene functions can result in adverse drug reactions or drug inefficacy. 
These reasons make phamacogenetics an important area of study. 
3. Basic pharmacology 
Pharmacology is the study that deals with interaction of endogenously administered 
chemical molecules termed drugs with living systems. It involves such studies like (i) 
Pharmacokinetics  (ii) Pharmacodynamics (iii) Toxicology  
i. Pharmacokinetics : Pharmacokinetics is the quantitative study of drug movement from 
administration throughout out the body till excretion. All pharmacokinetic processes 
involve transport of the drug across cell membrane,. absorption, distribution and 
excretion 
ii. Pharmacodynamics: Pharmacodynamics coined from two Greek words pharmacon; 
drugs and dynamis: power, involves the physiological and biochemical effect of drugs 
and their mechanism of action at organ, systemic, subcellular and macromolecular 
levels. The pharmacodynamic process describes all those matters concerned with the 
pharmacological action of a drug, whether they be determinants of the therapeutic 
effect or of the toxic effect. 
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iii. Toxicology: This is the study of poisonous effects of drugs and other chemicals. 
Although a speciality on it’s own, it is nevertheless still considered under 
pharmacology with regards to adverse drug effects. 
3.1 Principles of drug actions  
There are eight  main drug actions and these are: 
Stimulation: Through direct receptor agonism and downstream effect e.g. adrenaline 
stimulates heart, pilocarpine stimuates salivary glands. However, excessive stimulation is 
often followed by depression of that function e.g. high dose of picrotoxin, a CNS stimulant, 
produces convulsions followed by coma and respiratory depression. 
Depression: Through direct receptor agonism and down stream effect e.g. barbiturates 
depress CNS while quinines depresses the heart. The action of this mechanism is selective. 
Blocking/Antagonizing action: The drugs binds the receptor but does not activate it. 
Stabilizing action: In this case, the drugs seem to act neither as a stimulant nor as a 
depressant but to stabilize general receptor activation like buprenorphine in opioid 
dependence or aripiprazole in schizophrenia. 
Replacement: Refers to the use of natural metabolites including hormones and vitamins in 
deficiency stages e.g. levodopa in Parkinsonism, insulin in diabetes mellitus, iron in anemia 
and oestrogen replacement  in women of menopausal age.     
Direct beneficial chemical reaction: As in use of antioxidants like Vitamins C,E and B-
carotene for free radical scavenging  
Cytotoxic action: Selective cytotoxic action for parasite, bacterial or cancer cells, attenuating 
them without significantly affecting the host cells e.g. use of  antibiotics like penicillin, 
zidovudin and cyclophosphamide  
Irritation: A none selective often noxious effect applicable to less specialized cells, for 
example the epithelial, connective tissue cells). Mild irritation may stimulate associated 
function e.g. bitters increase salivary and gastric secretions which results in increased blood 
flow to the site. However, strong irritation may result in inflammation, corrosion, necrosis 
and morphological damage with resultant diminution or loss of function. Therefore caution 
should be exercised in the administration because of tendency of excessive ingestion. 
4. Metabolism of drug and other xenobiotics  
Metabolism of drugs and other xenobiotics involves activities that modify the chemical 
structure of the substances which are foreign to the body’s internal mileu. These reactions 
often act to detoxify poisonous compounds; however in some cases, the intermediate 
metabolite can themselves be toxic  
The purpose of biotransformation is to convert lypophilic compounds to hydrophilic  ones 
which will facilitate their excretion. The consequences of biotransformation is changes in 
pharmacokinetic characteristics. 
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Xenobiotics metabolism can be divided into three phases. In phase 1, enzymes such as 
cytochrome p450 oxidases introduce an active or polar group into the xenobiotics. These 
modified compounds are then conjugated to polar compounds in phase II reactions. The 
main enzyme that catalyses the reactions in phase II is glutathione S-transferase since it acts 
on a wide range of substrates. 
The final phase; phase III may involve further metabolism of conjugates of phase II reactions 
like the processing of glutathione conjugates to acetylcysteine (mercapturic acic) conjugates 
before being recognized by efflux transporters and pumped out of the cells (Boyland & 
Chassaud 1969, Thomalley 1990) 
Peculiar to all organisms is the possession of cell membranes which serve as hydrophobic 
permeability barriers to control access to their internal environment. Polar compounds 
cannot diffuse across these cell membranes, and the uptake of useful molecules is mediated 
through transport proteins that specifically select substrates from the extracellular mixture. 
The implication of this  structure is that most hydrophilic molecules cannot enter the cells 
since they need to be recognized by specific transporters (Mizuno et al 2003). 
The detoxification of reactive by-products is via a different mechanism. Because these 
species are derived from normal cellular constituents, they usually share the same polar 
characteristics therefore, specific designated enzymes can metabolize them. A notable 
example of these specific detoxification system is the glyoxalase system which catalyses the 
removal of the reactive aldehyde, methylglyoxal (Thormalley 1990) and the various 
antioxidant systems that eliminate reactive oxygen species   (Sies 1997). 
4.1 Phase I reactions 
In Phase I reactions, a variety of enzymes act to introduce reactive and polar groups into 
their substrates. This is basically a functionalization reaction. One of the most common 
modifications in this phase is hydroxylation, a reaction catalysed by the cytochrome P-450 
dependent mixed function oxidase system. These enzymes complexes act to incorporate an 
atom of oxygen into nonactivated hydrocarbons, which can result in either the introduction 
of hydroxyl groups, or Nitrogen, Oxygen.and Sulphate- dealkylation of substrates 
(Schlichting et al 2000).Of all the enzymes involved in drug metabolism, the cytochrome 
P450.(CYP450) is regarded as the most important because many drugs are  substrates for the 
enzymes of the group. In all, CYP3A4, CYP2D6, CYP2C9, CYP219, CYP2B6 and CYP1A2 
subtypes play the most critical role and account for more than 90% of drugs metabolized by 
CYP 450 enzymes ( Evans & Relling 1999). These enzymes have proven genetic 
polymorphism with associated drug responses (Hiratsuka et al 2002, Wong et al 2005, 
McAlpine et al 2011) and racial variations (Meyer 2004 & Suarez – Kurtz 2005). 
Phenotypes of P450 are divided into four groups and these are; the extensive metabolizers 
(EM)who show low metabolic activities, the poor metabolisers(PM )who carry gene 
alterations on both alleles which are inherited in an autosomal manner, the intermediate 
metabolizers (IM) with metabolic capacity in between those of PM and EM and finally the 
ultra rapid metabolizers (UM )who show higher metabolic capacity than the EM. (Murphy 
2001, Hiratsuka et al 2005). Genetic variations have been observed particularly with CYP 
2D6, CYP2C9 and CYP2C19 genotypes (Ingelman – Sundberg 1999, Hiratsuka 2006). With 
regards to  CYP2D6,five to ten percent of caucasians are poor metabolizers and have little 
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enzyme activities. In addition, there is a distinct racial diversity in the frequency of the 
classes. Examples of CYP450 catalyzed drug metabolic reactions include 
i. Hydroxylation: S-mephenytoin CYP3A4 4-OH-S-mephenytoin 
ii. Epoxidation: Carbamazepine CYP3A4/5 10,11 Epoxide  
iii. Oxygenation: Amines CYP 2D6 Hydroxylamines 
iv. O-dealkylation: Dextromethorphan CYP2D6 Dextrophan  
v. N-demethylation: Caffeine CYP2E1 Theobromine  
vi. N-demethylation: Caffeine CYP1A2 Paraxanthine  
vii. N-demethylation  Caffeine CYP2E1 Theophylline 
viii. Oxidative Group Transfer: Parathion CYP2B6 Paraoxon  
ix. Dehydrogenation:  Acetaminophen CYP2E1 N-Aacetyl benzoquinoneimine 
x. Ester Cleavage: Loratidine CYP3A4, CYP2D6 Desacetylated Loratidine  
xi. Reduction: Paraquat FLAVOPROTEIN REDUCTASE paraquat radicals 
4.1.1 Non P450 enzyme catalysis 
Besides the CYP 450 enzymes, other enzymes that participate in drug biotransformations 
include; monoamineoxidases, peroxidases, lactoperoxidases myeloperoxidases, prostaglandin-
H-synthetase and flavin-containing monooxygenases.(FMO).Examples of the reactions they 
catalyse include: 
i. Hydrolysis: hydrolysis of peptide  bond of Insulin 
ii. Reduction:  Chloral Hydrate ALC. DEHYDROGENASE Trichloroethanol 
iii. Oxidoreduction: Alcohol ALC.DEHYDROGENASE Aldehyde  
4.2 Phase II reactions 
In phase II reactions, the activated xenobiotic metabolites are conjugated with charged 
species such as glutathione (GSH), sulfate, glycine or glycuronic acid and increased risk of 
early renal complications in type 2 diabetes mellitus (Banjoko & Akinlade 2010). These 
reactions are catalysed by substrate specific transferases which in total can metabolize 
almost any hydrophobic compound that contains nucleophilic or electrophilic group. 
One of the most important of this group is the glutathione S-transferase (GSTs). The 
addition of large anionic groups such as glutathione detoxifies reactive electrophiles and 
produces more polar metabolites that cannot diffuse across membranes and may therefore 
be actively transported. 
4.2.1 Glutathione conjugation 
Glutathione is a tripeptide of glycine, cysteine and glutamic acid formed by the action of 
glutamylcysteine synthetase (glutathione synthetase).The enzyme glutathione transferase 
catalyses the conjugation of modified xenobiotic with glutathione. A large number of drugs 
are conjugated by glutathione during metabolism. Inhibitors of the enzyme include 
Buthione – S – Sulfoxine. Two types of reactions are common with glutathione. The first is 
displacement of halogen, sulfate, sulfonate or phosphonitro group. The second is the 
addition of glutathione to activated double bond or strained ring system. Some of the 
conjugation reactions include:  
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i. N – acetylbenzoquinoneimine, an activated metabolic of acetaminophen.  
ii. O – demethylation of organophosphates  
iii. Activation of trinitroglycine to oxidized glutathione (GSSG) dinitroglycerine and Nitric 
oxide (NO) a vasodilator.  
Distinct cytosolic and microsomal glutathione -S transferases have been identified. In all, 
four classes of soluble glutathione S transferase are known to exist. The enzyme also exhibit 
genetic polymorphism and overexpression of the enzyme leads to e.g. resistance of insects to 
DDT, corn to atrazine and cancer cells to chemotherapy. The enzyme also participates in 
reduction of hydroperoxides and prostaglandin metabolism. Inducers of the enzyme include 
3-methylcholanthrene, phenobarbital, corticosteroids and antioxidants.  GST exhibit specie 
specificity; for example, aflatoxin B1 is not carcinogenic in mice because it  conjugates with 
glutathione very rapidly in them. Conjugates are excreted intact in bile or converted to 
mercapturic acid in kidney and excreted in urine in a reaction catalysed by glutamyl 
transpeptidase an aminopeptidase  
4.2.2 Uridyl Diphosphate Glucuronyl transferase (UDPG transferase) 
The reaction of UDP Glucuronyl transferase results in the formation of O-, N-, S and C- 
glucuronides. Six forms of this enzyme have been identified in the liver. The cofactor for its 
reaction is UDP – glucuronic acid. Inducers include phenobarbital, indoles, 3 methyl 
cholanthrene and cigarette smoke. Some of its substrate are dextrophan, methalidone, 
morphine, p-nitrophenol, valproic acid, non steroidal anti-inflamatory drugs, bilirubin and 
steroid hormones. In Criggler Najjar syndrome; a severe form of bilirubinaemia, the enzyme 
is inactive hence inducers have no effect. However, in Gilbert’s syndrome; a mild form of 
hyperbilirubinaemia, phenobarbital can increase the rate of bilirubin glucuronidation to 
normal functions . Other substrates of the enzymes include, morphine and chloramphenicol. 
Conjugates of UDPG transferase are excreted in bile and urine. An S-glucuronidase from the 
gut microflora cleaves the glucuronic acid, the glycone formed can be reabsorbed to 
undergo enterohepatic cycling. Other associated reactions include metabolic activation of 2, 
6 dinitrotoluene by S-glucuronidase; whereby the latter removes glucuronic acid from N-
glucuronide. The nitrogroup is then reduced by microbial N-reductase and the resultant 
hepatocarcinogen may be reabsorbed. 
4.2.3 Sulfation  
The sulfation process is catalysed by sulfotransferases which are widely distributed in the 
body. The co-factor for their reaction is 31 phosphoadenosine 5 phosphosulfate (PAPS). 
Their conjugation result in highly water soluble sulfate esters which are eliminated in urine 
and bile. Examples of substances for sulfation include phenols, catecholamines and 
hydroxylamines. Sulfation is a high affinity, low capacity pathway which is limited by low 
PAPS level. Acetaminophen is a drug that undergoes both sulfation and glucuronidation. At 
low doses, sulfation predominates but at high doses glucuronidation predominates. Four 
sulfotransferases in human liver cytosol have been identified to date. Aryl sulfatases in gut 
microflora remove sulfate groups in a sort of enterohepatic recycling. Sulfation decreases 
pharmacologic and toxic activities but can also cause activation of chemically unstable 
groups to carcinogens, for example hydroxylamine. 
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4.2.4 Methylation  
This is a common minor pathway of xenobiotic biotransformation which generally decreases 
water solubility. Enzymes that catalyse the reactions are called methyltransferases and the 
co-factor is S-adenosylmethionine (SAM). In methylation, a methyl group (CH3) is 
transferred to O, N, S or C molecule  on the substrates which include phenols, 
catecholamines and heavy metals like Hg, As and Se. There are several methyltransferases 
in human tissues examples of which are phenol – O – methyltransferases, catechol – O – 
methyltransferase, O-methyl transferase and S-methyl transferase. Genetic polymorpohism 
has been observed in thiopurine metabolism in a reaction catalysed by a member of this 
group of enzymes. High activity allele causes increased toxicity and low activity allele 
causes decreased efficacy. 
4.2.5 Acetylation 
This is the major route of biotransformation of aromatic amines and hydrazines. The 
reaction is catalysed by N – acetyl transferases (NAT) enzyme and the co factor acetyl-
coenzyme-A. The process generally causes a decrease in water solubility. Substrates of  the 
enzyme include sulfanilamide, isoniazid, dapsone and caffeine. In humans three phenotypic  
forms have been identified and these are slow, intermediate and rapid acetylators (Evans 
1999, Murphy 2001). Various mutations of the enzyme result in decreased enzyme activity 
or stability. Like every other entity exhibiting genetic polymorphism, there are various 
ethnic and tribal variations. For example, 70%  of slow acetylator status was observed in 
Middle Eastern population, 50% in Caucasians and 25% in Asians (Hiratsuka 2006, Evans 
and Relling 1989). Drug toxicities in slow acetylators include nerve damage from dapsone 
and bladder cancer in cigarette smokers due to increased levels of hydroxylamines (Ohno 
and Yamaguchi 2000, Evans 1999, Hiratsuka et al 2006). 
4.2.6 Amino acid conjugation  
This is an alternative pathway to glucuronidation. Amino acid conjugation operate with two 
principles. The first is that carboxylic group (COOH) group of a substrate is  conjugated 
with an amino (NH2) group of glycine, serine, glutamine requiring co enzyme-A  activation.  
Notable example is the conjugation of benzoic  acid with glycine to form hippuric acid. 
Benzoic acid is commonly used as a preservative in carbonated drinks. Alternatively 
aromatic NH2 or NHOH conjugate with COOH of serine proteins requiring ATP activation. 
This metabolic pathway  demonstrate specie specificity in accepting amino acid. For 
example, in mammals, benzoic acid is conjugated by glycine whereas for the same substrate 
in birds, ornithine acts. Dogs and cats utilize taurine to conjugate bile acids while other non 
human primates utilize glutamine for conjugation. Metabolic activation of serine or proline 
results in N-esters of hydroxylamine which are unstable and may degrade to reactive 
electrophile. 
4.2.7 Ribonucleoside/nucleoside synthesis 
This pathway is important for the activation of many purine and pyrimidine antimetabolites 
used in cancer chemotherapy 
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4.3 Phase III reactions 
Phase III reactions can be described as a stage of further modification and excretion. 
Although many authors do not regard this phase as a distinct phase,  current knowledge of 
efflux transporters tend to support the categorization.  A common example is the processing 
of glutathione conjugates to acetylcysteine (mercapturic acid) conjugates (Boyland and 
Chassaud 1969). In this scenario, glutamate and glycine residing  in the glutathione 
molecule are removed by gamma-glutamyltranspeptidase and dipeptidases. Finally, the 
cysteine residue in the conjugate is acetylated .The conjugates and their metabolites can then  
be excreted from cells in phase III of their metabolism with anionic groups acting as affinity 
taps for a variety of membrane transporters of the multidrug resistance protein (MRP) 
family (Homolya et al 2003). These proteins are members of the family of ATP-binding 
cassette transporters and can facilitate the ATP dependent transport of a large varieties of 
hydrophobic ions (Konig et al 1999) and thus act to remove phase II products to the 
extracellular medium, where they may be further metabolized and excreted (Commandeur 
et al 1995). 
Since the discovery of permeability glycoprotein (P – glycoprotein) complex; an initial 
member of the ATP binding cassette (ABC) family of drug transporters by Juliano and Ling 
in 1976, (Juliano and Ling 1976) research into this group of proteins has been  gaining wide 
interests. Some of the membrane transporters confer on the cells the ability to be resistant 
not only to the selective agent but also  to a broad spectrum of structurally and functionally 
distinct antibiotics and alkaloids.This phenotypic character is referred to as multiple drug 
resistance (MDR). The MDR genotype/phenotype relationship is complex with over 18  
ABC genes associated with human disease (Dean and Annilo 2005). 
In addition to the ABC transporters, other important drug/xenobiotic transporters include the 
organic cation transporters of the SLC 22A super family and the organic anion transporting 
peptides of the SLC21  superfamily (Hagenbuch 2010). It is expected that with the growing 
interests in this phase of drug metabolism, investigations on the transcriptional regulatory 
control of this important transport system in target  organs such as the liver, kidney and 
central nervous system will become intense in the next few decades (Omiecinski 2011). 
5. Target genes of pharmacogenetics  
About 20 kinds of enzymes are involved in metabolism of drugs. The cytochrome enzyme 
(CYP450) is regarded as the most important enzyme in drug metabolism. About 15 types of 
this group have been identified in human beings where they catalyse the biotransformation 
of many xenobiotics. Other enzymes include thiopurine methyl transferase (TMPT) which 
metabolizes 6- mercaptopurine and azathioprine, uridyl diphosphate glucuronyl transferase 
(UDGT) responsible for the conjugation of bilirubin, N – acetyltransferase (NAT2) 
responsible for metabolism of sulpha containing drugs and caffeine, catachol – o – methyl 
transferase (COMT) responsible for the metabolism of levodopa and dihydropyrimidine 
dehydrogenase (DPD) a rate limiting enzyme for the metabolism of 5 – florouracil (5 FU). 
Genetic polymorphism has been identified in many of these enzymes with varying degrees 
of drug response (Evans & Relling 1999, Furuta et al 2001,  McAlpine et al 2001,Suzuki et al 
2011) Of all the enzymes involved in drug metabolism, the cytochrome P450.(CYP450) is 
regarded as the most important because many drugs are substrates for the enzyme of the 
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group. CYP3A4, CYP2D6, CYP2C9, CYP219, CYP2B6 and CYP1A2 play the most critical role 
and account for more than 90% of drugs metabolized by P450 ( Evans & Relling 1999). These 
enzymes have proven genetic polymorphism with associated drug responses (Hiratsuka et 
al 2002, Wong et al 2005, McAlpine et al 2011) and racial variations (Meyer 2004 & Suarez – 
Kurtz 2005). As discussed  earlier, genetic polymorphism can manifest at both 
pharmacokinetic and pharmacodynamic  levels whereby many genetic variants of 
respective enzymes, membrane transporters, receptors and ion channels have been 
dectected ( Wiesler et al 2008,  Phipps – Green et al 2010 & Bouamar et al 2011) 
5.1 Pharmacokinetic related genes 
5.1.1 Genes of phase i reaction enzymes  
Genetic variations have been observed particularly with CYP2D6, CYP2C9 aand CYP2C19 
genotypes (Ingelman – Sundberg 1999, Hiratsuka 2006) and therefore will be further 
elucidated. 
i. CYP2D6: With regards to this CYP subtype, 5 – 10% of Caucasians are poor 
metabolizers and have little enzyme activity and there is a distinct racial diversity in the 
frequency of the classes. About 50 genetic polymorphisms of CYP2D6 have been 
reported. The popular ones are CYP2D6*3, CYP2D6*4 and CYP2D6*5. More than 90% of 
PMs in Caucasians are ascribable to these three genetic polymorphism (Daly et al 
1996,& Suzuki et al 2011). In blacks, the common variant is CYP2D*17 (Evans 1989) 
ii. CYP2C9: is involved in the metabolism of an epileptic agent; phenytoin and an 
anticoagulant; warfarin. To date, 12 CYP2C9 variants have been reported. For example 
in cases with phenytoin, oral clearance decreased to one quarter in  subjects with 
homozygous polymorphism for CYP2CP*3 (Kidd et al 1999 , Scodo et al 2002, Linder et 
al 2009). Many studies focused on CYP2C9 polymorphism to link variability with 
warfarin therapy. However only about 10% of dosage variation can be attributed to 
CYP2C9 polymorphism. It is thought that environmental and genetic factors can 
influence warfarin response therefore dosage is individualized based on sex, age, 
vitatmin K intake, and disease states. Warfarin dosing can be challenging because of its 
narrow therapeutic index and the serious risk of bleeding in  overdosage. Warfarin 
exerts its anticoagulant effects by inhibiting hepatic vitamin K epoxide reductase; an 
enzyme involved in the vitamin K epoxide reductase complex sub unit 1 (VKORC1). 
The gene that encodes this enzyme has been identified and is believed to contribute to 
the variability in warfarin response (Scodo et al 2002, Aquilante et al 2006, Linder et al 
2009, Guengerich 2001).  
iii. The CYP2C19: enzyme metabolizes many drugs including the proton pump inhibitor; 
citalopram (lelexa) diazepam (valium) and imipramine (toranil). More than 16 variants 
of CYP2C19 associated with deficient, reduced, normal or increased activity have been 
identified. The most  common genotypic variants for poor metabolizers are CYP2C19*2 
and CYP2C19*3. The CYP2C19*17 variant is associated with ultrarapid metabolizers 
and seems to be common in Swedes (18%), Ethiopians (18%) and Chinese (4%). (Sum et 
al 2006). The proton pump inhibitor omeprazole (prilosec) is primarily metabolized by 
CYP2C19 to its inactive metabolite 5 – hydroxyl-omeprazole. Individuals who  are 
CYP2C19 poor metabolizers can have five fold higher blood concentrations of 
omeprazole and experience superior acid suppression and higher cure rate than the rest 
www.intechopen.com
 Pharmacology 
 
192 
of the population. Conversely, blood concentrations of omeprazole are predicted to be 
40% lower in ultrarapid  metabolizers than the rest of the population and are therefore  
at risk of therapeutic failure. (Sum et al 2006) 
5.1.2 Genes of phase II reaction enzymes  
N – Acetyl Transferase: Activities of human hepatic drug metabolizing enzymes was earlier 
been recognized as a cause of inter – individual variation in the metabolism of drugs. 
Therefore acetylation of many drugs like isoniazid caffeine, nitrozepam and sulphonamide 
exhibit genetic polymorphism. The N – acetyl transferase (NAT) enzyme is controlled by 
two genes, (NAT 1) and (NAT 2) of which NAT2 A and B are responsible for clinically 
significant metabolic polymorphism. (Heiss 1988, Grant et al 1990). Three phenotypes have 
been recognized with activities of NAT2 and these are rapid acetylator (RA), intermediate 
acetylator (IA) and slow acetylator (SA) status (Cranswick 2005). The frequency of  slow 
acetylator in Caucasians and Negro populations is 50% and 10% in Oriental groups. (.Evans 
D.A 1989) Slow acetylator phenotype is preponderant among different Arab populations 
irrespective of geographical location of the country. (Woolhouse et al 1997, At- Moussa et al 
2002 & Desoky et al 2005). Three genetic polymorphisms NAT2*5, NAT2*6, NAT2*7 but not 
NAT2*4 (wild type allele) are responsible for almost all SAs in the Japanese (Huang et al 
2002) Drug induced hepatitis caused by isoniazid occurs often in SA than RA (Ohno et al 
2000) and Type II diabetes SA may be predisposed to progression to renal complications 
than their RA counterparts (Banjoko & Akinlade 2010). 
Thiopurine - S –Methyl Transferase (TPMT: Catalyses the S – Methylation of the 
thiopurine agents, azathioprine, mercaptopurine and thiogleamine. These agents are 
commonly used for a diverse range of medical indications including leukaemia, rheumatic 
diseases and organ transplant. The principal cytotoxic mechanism of these agents is 
mediated via incorporation of thioguanine nucleotides (TGN) into DNA. Thiopurines are 
inactive prodrugs that require metabolism to thioguanine nucleotides to exert cytotoxicity. 
This activation is catalyzed by a multienzyme pathway which include hypoxanthine 
phosphoribosyl transeferase (HPRT), oxidation by xanthine oxidase (XO) or methylation by 
TPMT. During metabolism, hypoxanthine-guanine phosphoribosyl transferase (HPGRT) 
converts 6-mercaptopurine to cytotoxic6-thioguanine nucleotide analogues, while 
thiopurine methyl transferase (TPMT) inactivates 6-mercaptopurine through methylation to 
form 6 –methylmercaptopurine. However, TMPT is the major pathway and it  is highly 
variable and polymorphic. More than 12 TPMT alleles have been identified. The most 
common ones are TPMT*2, TPMT*3A, TPMT*3C, with all three associated with lower 
enzyme activity attributable to enhanced rates of proteolysis of the variant proteins (Donnan 
et al 2011, Haghuid et al 2011, Guengerich 2001). Caucasian infant patients with acute 
myeloid leukaemia carrying TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C showed significantly 
higher concentrations of the thiopurine intermediate metabolite 6-mercaptopurine in their 
red cells that requires dose reduction or termination of thiopurine administration due to 
adverse effects such as myelosuppression (Relling et al 1999, Tavadia et al 2001). 
Dihydro Pyrimidine Dehydrogenase (DPD): Dihydro pyrimidine dehydrogenase (DPD) is 
a rate limiting enzyme for the metabolism of the anti cancer drug; 5 fluorouracil (5FU). With  
DPD being responsible for over 50% of its biotransformation. Other substrates for DPD are 
carmofur, tegafur and doxifluridine. The gene encoding for DPD is DPDY and about 13 
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genetic variants have been reported (McLeod et al 1998, Collie – Duguid et al 2000). The 
genetic variant that is responsible for decreased DPD activity has been reported to be 
DPYD*2 with a polymorphism at the splicing recognition site. (Wei at al 1996) 
Administration of 5 – FU to the patients with decreased enzyme activity results in adverse 
effects such as leukocytopenia, stomatitis, diarrhea, nausea and vomiting (Etienne et al 1994) 
Glutathione – S – Tranferase (GST): GSTs and the human genes encoding these enzymes 
are highly polymorphic with about 50% and 25% of most populations having a mutation or 
complete deletion of these gene respectively rendering them deficient or lacking the 
enzyme. Major racial and ethnic differences exist and GST M and GST T1 are the major 
genes. Other GSTs include GST P1 and GST*A which are also subject to genetic 
polymorphism and have been implicated in resistance to anti cancer drugs. High GST 
activity has been associated with decreased risk of haematologic relapse, central nervous 
system response and improved prednisolone response. (Commandeur et.al 1995) Inherited 
GST – P1 allele encoding for the 11e 105 Val. amino acid substitution, has been associated 
with improved overall breast cancer survival compared with patients who have at least one 
wild type GST P1 allele. Conversely in patients with acute myeloid leukaemia treated with 
high doses of combination therapy, the homozygous GST – T1 deletion is associated with a 
higher risk of toxic death during remission. ( Arruda et. al 2001)   
Uridyl Diphosphate Glucuronyl Transferase (UGT): The UDP – glucuronyl transferase 
(UGT) belongs to a super family of membrane bound proteins localized in the endoplamic 
reticulum and are responsible for glucuronidation of many xenobiotics and endobiotics. The 
UGT genes have been classified into families and sub families based on evolutionary 
divergence with all known human UGT’s being in the UGT1A 2A and 2B sub families. 
(Mackenzie et al 1997, Randominska – Pandya et al 1999, Tukey & Strassburg 2000). To date, 
polymorphism in UGTA1 have been more studied extensively and seem to have clinical 
significance. The anticancer drug irinotecan is metabolized by the enzyme and 
polymorphism resembling condition seen in Gilbert’s syndrome characterised by total lack 
of UGT enzyme due to deletion of the gene which leads to fifty fold reduction in irinotecan 
metabolism and such patients can be at risk of toxicity (Huang et al 2002 Desai et al 2003). 
5.1.3 Phase III reactions: Transporter genes 
Membrane transporters as mentioned earlier are heavily involved in drug clearance and 
alter drug disposition by actively transporting  drugs between organs and tissues. Therefore 
polymorphisms in the genes encoding these proteins may have significant effects on the 
absorption, distribution, metabolism and excretion of xenobiotics and may alter the 
pharmacodynamics of these agents. Uptake transporters are required for the uptake  of 
some drugs into the cell whereas efflux transporters are responsible for pumping some 
drugs out of cells or preventing them from ever getting in. Transporters are also thought to 
be involved in drug – drug reactions. 
The most important families of the transporters include (i) ATP binding cassette (ABC) 
family whose genes include important members like the multi drug resistance gene also 
classified as ABCB 1 i.e. (ABCB1/MDR1), ABCC1, ABCC2, uric acid transporter (ABCG2), 
breast cancer resistance protein BCRP also classified ABCG2 i.e. (BCRP/ABCG2).(ii) The 
solute transporter superfamily (SLC) which include the organic anion transport polypeptide 
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(SLC 21/OATP), organic cation transporter SLC 22 OCT), zwitterion/cation transporter 
(OCTNs), folate transporter(SLC19A1), neurotransmitter 
transporter(SLC6,SLC17,&SLC18)and serotonin transporter (5HTT).Genetic polymorphism 
in drug transporter genes have increasingly been recognized as a possible mechanism 
accounting for variation in drug response because these transporters play important roles in 
the gastrointestinal absorption, biliary and renal elimination and distribution to target sites 
of their substrates. (Meier et al 2007, Shu et al 2007, Choi & Song 2008) 
5.1.3.1 The ABC family  genes 
ABCB1: Refers to ATP binding cassette (ABC) sub family B member 1, or MDR 1 also 
designated cluster of differentiation (CD243) is the permeability glycoprotein (P – 
glycoprotein).ABC genes are divided into seven distinct sub families (ABC1, MDR/TAP, 
MRP, ALD, OABP, CaCW 20 andWhite). Members of the MDR/TAP sub- family are 
involved in multi drug resistance. The protein encoded by this gene is an ATP dependent 
drug efflux pump of xenobiotics with broad substrate specificity. It is responsible for 
decreased drug accumulation in multi drug resistant cells and often mediates the 
development of resistance to cancer cells (Viguie 1998 ). This protein also function as a 
transporter in the blood brain barrier (Viguie 1998, Phipps – Green et al 2010). It likely 
evolved as a defense mechanism against harmful substances. Some  of the functions of 
protein encoded by ABCB 1 gene include regulation of distribution and bioavailability of 
drugs, removal of metabolites and xenobiotics from cells into urine, bile and intestinal 
lumen, transport of compounds out of the brain across the blood – brain barrier, digoxin 
uptake, prevention of invermectin entry into the central nervous system and protection of 
hamatopoietic cells from toxins (Dean  2002.) Mutation of ABCB1 gene will therefore result 
in disruption of these functions. The activity of the transporter can be determined by both 
membrane ATPase and cellular calcein assays. Drug resistance had been observed in M89T, 
L662R, R669 and S1141T variants of the gene and decreased drug efficacy in W1108R 
variant. In addition, genetic variation in ABCB1 has been associated with both toxicity and 
drug response in  5Fluoro-uracil (Gonzalez – Haba et al 2011) and pacilitaxel therapy 
(Henningson et al 2011). 
ABCC 1 genes: Multidrug resistant protein 1 (MRP1) an ATP bounding cassette transporter 
encoded by ABCC 1 gene is expressed in many tissues and function as an efflux transporter 
for glutathione, glycine  and sulphate conjugates as well as unconjugated substrates. An 
evaluation of single nucleotide polymorphism (SNP) revealed 7 mutations in the gene 
(Colombo et al 2005) while in a Japanese study, 86 genetic variants were identified 
(Fukushina – Uesaka et al 2007). Mutations in ABC transporters cause or contribute to many 
different Mendelian and complex disorders including adrenoleukodystrophy, cystic fibrosis 
and retinal degeneration (Dean & Annilo 2005). There has been no evidence of clinical 
significance in studies of the variants. (Colombo et al 2005, Pauli Magrus & Kroetz 2005 & 
Fukushina -Uesaka 2007). 
ABCC2 gene: ABBCC2 genes codes for the ABCC2 or MRP2 protein. (MRP2) is an export 
pump expressed at tissue barriers. Genetic variants 24 e>T, 1249Ca>A and 3972 > T had been 
observed and are thought to cause inter individual differences of bioavailability of various 
endogenous and exogenous compounds (Colombo et al 2005, Laechelt et al 2011). About 27 
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other variants have also been detected (Colombo et al 2005). A haplotype dependent influence 
on transport capacity of ABCC2 had been observed but seems to be mainly based on post 
transcriptional modifications rather than transport rates (Laechelt et al 2011).  
TheABCG2 gene  encodes an inhibitor of breast cancer resistance protein (BCRP) (ABCG2) 
protein, another member of the ABC transporter. The protein confers protection against the 
development of breast cancers. Evaluation of single nucleotide polymorphism identified 16 
variants (Morisaki et al 2005, Colombo et al 2005). Genetic polymorphism in ABCG2 might 
alter the transport activity of some drugs causing therapy in drugs like irinotecan, to cause 
severe myelosuppression (Choi et al 2009, Hampras et al 2010). A polymorphism, C421A 
observed in human placenta is not a genetic variant acting in cis but is considered to 
influence the translational efficiency (Kobayeshi et al 2005). Another genetic variant 
(ABCG2) (rs 2231142, Q141K) encoding a uric acid transporter is associated with gout in 
diverse populations (Phipps – Green et al 2010) 
5.1.3.2 Solute Carrier Superfamily: (SLC) Genes 
The solute carrier (SLC) superfamily of transporters consists of more than 300 members 
subdivided into 47 families. They are expressed in most tissues but primarily in liver, lungs, 
kidney and intestine. 
i. OATP/SLC21: Organic anion transporter facilitates movement of anion across the cell 
membrane.OATP1B and OATP1B3 are human hepatocyte transporters that mediate the 
uptake of various endogenous and exogenous substrates. Genetic variation was 
observed in the SLCO1B1 and SLCO1B3 genes which encode OATP1B1 and OATP1B3 
proteins. Forty nine (49) and 41 nucleotide sequence variants leading to 10 and 9 in 
SLCO1B1 and SLCO1B3 genes respectively were identified (Bowin  et al 2010). 
Furthermore, in OATPC (SLC21A6) and OATP3 (SLC22A8) genes, polymorphism did 
not appear to be associated with changes in renal and tubular secretory clearance in the 
latter but the former was associated with differences in the disposition kinetics of 
pravastin. Individualswith the OATP – C*15 allele (ASP 130 Ala 174) had a reduced 
total and non renal clearance compared with those of OATPC*15 allele (ASP130Val 174) 
(Nishizato Y et al 2003). 
ii. SLC 19A1 (Folate Transporter)member 1: The SLC19A1 are the proteins responsible for 
the transport of folate. Transport of folate into the mammalian cells can occur via 
receptor mediated (folate receptor 1) or carrier mediated (SLC19A1) mechanism.  
Methotrexate is an antifolate chemotherapeutic agent that is actively transported by the 
carrier mediated uptake system. Individuals carrying a specific polymorphism of 
SLC19A1 gene ï.e (C80GG) have lower levels of folate. (Whetsine 2003, Matherly et al 
2007) and those carrying the C80AA genotype treated with methrotrexate have higher 
levels of this antifolate chemotherapeutic agent. This underpins requirements for 
personalized dosing with the drug based on patients genotype  
iii. OCT/SLC22: Most solute carrier transporters are localized at either the basolateral or 
apical plasma membrane of polarized cells but some are also expressed in mitochondria 
and other organelles (Wojtal et al 2009). The genes encoding the three organic cation 
transporter isoforms OCT1, OCT2 and OCT 3 are clustered together on the long arm of 
chromosome 8 in  humans and carry out functions of transport of small organic cations 
with different molecular structures independent of sodium gradient. These organic 
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cation substrate include drugs like metformin, procainamide and cimetidine as well as 
endogenous compounds like dopamine and norepinephrine and toxic substances like 
tetraethylammonium bromide (TEA) (Kang et al 2007). 
5.2 Pharmacodynamic related genes 
i. Receptors: Many receptors are involved with several signaling pathways. Example of 
which is epidermal growth factor receptor( EGFR). This receptor has been implicated in 
the oncogenesis and progression of several solid tumours thereby being identified as a 
suitable target for anticancer treatment. Polymorphism has been observed in the 
development of cancer on dinucleotide repeats in intron 1 of the EGFR gene and this 
has correlated with EGFR expression with therapeutic implication for treatment with 
tyrosinase kinase inhibitor. A higher proportion of Asians do overexpress EGFR that 
may influence their responses to tyrosine kinase inhibitor (Tan et al 2004). 
G-protein Coupled Receptors (GPCR):Over 50% of all drug targets have G-protein 
coupled receptors (GPCR). Genes of GPR has  more coding regions than non – GPCR 
genes making them more important for pharmacological investigations.  
GABAA Receptor Mutation in GABAA receptor ion channel may be a reason for the 
diminished protection of anti epileptic drugs.  
Insulin Receptor(INSR): The receptor is important in the management of diabetes 
mellitus patients and mutation of the gene encoding the receptor will result in poor 
response particularly in type 2 diabetes.Mutation of the gene  has also been suspected to 
contribute to genetic susceptibility to the polycystic ovarian syndrome(Siega et al2002)  
B2 Receptor: B2 agonist; albuterol (Proventil) is used to control acute attacks of asthma 
and are prescribed as needed .Patients with  2 receptor arginine genotype experience 
poor asthma control with frequent symptoms and a decreasing scores of poor 
exploratory volume compared with those with glycine genotype (Cowburn et al 1998, 
de Maat et al 1999). Seventeen (17%) of whites and 20% of blacks carry the arginine 
genotype (Wechsler et al 2005)  
ii. Ion Channels: Many genes encode for different ion channels including those of the 
central nervous system which include KCNJ10, KCNJ3, CLCN2, GABRA1, SCN1B and 
SCN1A. Some polymorphism of this channel has been linked to idiopathic generalized 
epilepsy (Lucarini et al 2007) 
The 5-HT3 receptor is a ligand-gated ion channel composed of five subunits.  To date, five 
different human subunits are known; 5-HT3A-E, which are encoded by the serotonin 
receptor genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E, respectively. Functional 
receptors are pentameric complexes of diverse composition. Different receptor subtypes 
seem to be involved in chemotheraphy-induced nausea and vomiting (CINV), irritable 
bowel syndrome and psychiatric disorders. 5-HTR3A and HTR3B polymorphisms may 
also contribute to the etiology of psychiatric disorders and serve as predictors in CINV 
and in the medical treatment of psychiatric patients. (Niesler et al 2008). 
iii. Enzymes: Polymorphism of pharmacokinetic enzymes no doubt influence the 
pharmacodynamics of drugs. However there are few enzymes that influence drugs at 
the point of actions one of these enzymes is the tyrosine kinase which modulate 
receptor activities. Therefore polymorphism in tyrosine kinase gene will affect drugs at 
the target point. 
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Another important enzyme of drug target is vitamin K epoxide reductase complex 
subunit 1(VKORC1). This enzyme is the drug target for warfarin an anticoagulant with 
a narrow therapeutic window and with serious consequences  of bleeding in the event 
of an overdose. Variation in maintenance dose of warfarin is largely attributable to 
genetic variants in the genes that encode the drug target VKORC1 the major 
metabolizing enzyme. The two genetic polymorphisms   explain 30 – 40% of the total 
variation in those on therapy.  
Angiotensin converting enzyme (ACE) genes encode for ACE, a target for ACE 
inhibitors which improves symptom and survival in cases of heart failure. Genetic 
polymorphism is suspected to be causing greater effects   of the drug in Europeans than 
Afro-Americans. Pre-treatment genetic screening is therefore apt to improve therapy 
iv. Neurotransmitter Transporters: Neurotransmitter transporters namely SLC6, SLC17 
and SLC18 families are primarily expressed in the neurons of the central and peripheral 
nervous system. These transporters are the sites of action of various drugs of abuse e.g 
cocaine, amphetamine and other clinically approved drugs like desipramine, reserpine, 
benztropine and tiagabine. Genetic variation in the SLC6, SLC17 and SLC18 encoding 
genes may result in altered expression and function of these proteins. In particular, 
antidepressants and antiepileptic drugs target these neurotransmitters as part of their 
primary mechanism of action. Therefore genetic variations may affect the efficacy of 
such drugs.   
6. Pharmacogenetic testing 
A genetic test is the analysis of human DNA, RNA chromosomes, proteins or certain 
metabolites in order to detect alterations related to a heritable disorder. This can be 
accomplished by directly examining the DNA or RNA that makes up a gene (Direct testing), 
looking at markers co-inherited with a disease causing gene (linkage testing), assaying 
certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic 
testing). Although genetic testing shares some features common with other kinds of 
laboratory testing, it is however unique in many ways and therefore requires special 
consideration .Pharmacogenetic testing can therefore be defined as utilization of 
aforementioned genetic biomarkers related to drug metabolism  and effects. A biomarker 
can be described as a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes to a therapeutic intervention (EMEA 2006) 
Methods of Pharmacogenetic testing depends on the biomarker to be assessed. These vary 
from simple spectrophotometric estimation of metabolites to DNA sequences, use of PCR 
and DNA probes, enzymes linked immunosorbent  assay, cell culture, gel electrophoresis 
high performance liquid chromatography and DNA hybridization techniques. It is not 
uncommon to use combined techniques to study clinical relevance of pharmacogenetic 
testing. 
Because information on pharmacogenetics is still evolving, there is a necessity for guidelines 
to be adopted for ethical reasons, economic considerations and patient benefit. Overall, the 
quest for pharmacogenetic information is likely to grow. As a matter of fact some drugs  
already carry labels addressing such. 
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6.1 European medicines agency guideline for pharmacogenetic testing  
The guidelines for European Medicines Agency  (EMEA) was desighned by the Agency’s 
committee for Human Medicinal Products (CHMP). The rationale for this guidelines include 
standardization, data analysis, interpretation, evaluation  of clinical relevance, ethical 
consideration and setting the stage for technical, scientific and regulatory issues. The 
guidelines addresses the following among other issues. 
i. Chosen design and rationale  
ii. the population selected for pharmacogenetic studies (i.e. species, age, gender and other 
variable related to the phenotype e.g. for human exposure ethnic group) 
*In the target population or relevant animal model 
*In the study population e.g. matched groups (responders/non responders, 
presence/absence of adverse events) 
iii. The population size selected for PG studies and a discussion on the power to detect an 
association in appropriate  
iv. Predictive values (positive and negative) of the PG biomarkers as per clinical     trials 
experience  
v. Assumptions on clinical utility e.g. benefit In using predictive pharmacogenetics testing 
versus other predictive biomarkers, use of a pharmacogenetic  biomarker as a segregation 
marker or as a stratification tool for a subpopulation in a general matching population. 
6.2 Pharmacogenetic testing and clinical benefits 
The overall purpose of PG testing is clinical benefits. Pharmacogenetic testing have resulted 
in some clinical benefit so far, some of which can be life saving. It was observed that roughly 
about 106,000 deaths and 2.2 million serious events caused by adverse drug reactions were 
reported yearly (Lazarom 1998) and 5 – 7% of hospital admissions in US and Europe lead to 
the withdrawal of 4% of new medicines with attendant financial loss. Since such drugs were 
linked to metabolizing enzymes with known polymorphism,prudence dictates suggestion of 
pharmacogenetic testing in indicated instances Pharmacogenetics testing is expectedly 
becoming commonly required particularly with drugs with low therapeutic window 
(Phillips et al 2001). However, the decision to use pharmacogenetic testing will be 
influenced by the relative costs of genotyping technologies and the cost of providing a 
treatment to a patient with an incompatible genotype. 
Notable clinical benefits of pharmacogenetic testing have been observed in NAT2 
genotyping for isoniazid treatment (Hiratsuka et al 2002, Weishilboum et al 2003, Gardiner 
and Begg 2006) andCYP2C19 genotyping for omeprazole treatment (Desta et al 2002). 
Others are TPMT genotyping for 6-mercaptopurine and azathioprine treatment (Relling et al 
1999, Gardener and Begg 2006) mtDNA A155G genotyping for aminoglycoside treatment 
(Cortopassi and Hatchin 1994, Usami et al 1999) CYP 2D6 genotyping for codeine treatment  
(Bradford 2002) Hepatitis C genotype for pegylated interferon – alpha – 2a or pegylated – 
interferon – alpha – 2b treatment. (Ingelman – Sundberg et al 2009, Thomas et al 2009) and 
Dihydropyrimidine dehydrogenese (DPI) testing for 5-fluoro-Uracil (5FU) treatment 
(Gionzalez and Fernandez –Salguero, 1995, McMurrough et al 1996, Wei et al 1996, Van 
Kuilenburg et al 1998). 
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There are currently requirements of pharmacogenetic testing of specific drugs before they 
can be prescribed and these include cetuximab, trastuzumab, maraviroc and dasatinib. In 
December 2007, the FDA recommended testing for HLA-B* 1502 allele in patients with 
Asian ancestry before initiating carbamazepine therapy because of high risk of developing 
carbamazepine induced Steven’s Johnson syndrome (SSS) or toxic epidermal necrolysis. 
Pharmacogenetic testing is also recommended for patients treated with warfarin, thiopurine, 
valproic acid, irinotecan, abacavir or rasburicase. 
Currently, drug labels contain information on pharmacogenetic tests which are classified as 
test required, test recommended and for  information only.  
7. Conclusion  
With the application of molecular biology methods and completion of the human genome 
projects and establishment of guidelines for pharmacogenetics practices and applications, it 
is expected that the interwoven field of pharnmacogenetics and pharmacogenomics will 
revoluntionise personalized medicine. Furthermore the field of predictive medicine is 
expected to receive a boost from pharmacogenetic information with attendant reduction in 
morbidity and mortality particularly from adverse drug reactions and therapeutic failure. 
With more intense researches and genotyping profiling, the challenges of standardization 
and interpretation of pharmacogenetic testing are apt to be overcome. It is worthy of note 
that currently some drug labels carry information on pharmacogenetic testing and 
requirements for therapeutic use. The promise of pharmacogenetics is therefore 
improvement of the overall health being of the patients. 
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